We set up to test the hypothesis of rs1689711 being a CHEK2:c.1100C risk modifier in larger sample collections, starting with 67 CHEK2 patients, as well as 688 non-carrier breast cancer cases and 246 healthy controls. Here, CHEK2 is linked to breast cancer.